Medicine & Health

Researchers at Washington University School of Medicine have found that immune cells stationed in such sinuses monitor the brain and initiate an immune response if they detect a problem.

A new study from Washington University School of Medicine suggests that a two-drug combination targeting a tumor’s energy sources could be as effective and less toxic than methotrexate, a long-used chemotherapy drug often given in high doses to treat osteosarcoma, a bone cancer.

Michael S. Kinch, associate vice chancellor and director of the Centers for Research Innovation in Biotechnology and Drug Discovery, and professor of biochemistry and molecular biophysics at the School of Medicine,, received a one-year $280,385 grant from Arnold Ventures for his research titled “CDEK: Clinical Data Experience Knowledge-base.”

Alex Holehouse, assistant professor of biochemistry and molecular biophysics at the School of Medicine, received a one-year $91,539 grant from Dewpoint Therapeutics for his research titled “Bioinformatic tools for the analysis of phase separating proteins.”

Researchers at Washington University School of Medicine have developed an imaging agent that could help refine assessments of kidney health, potentially salvaging some otherwise discarded donor kidneys.

WashU engineers have developed a biosensing microneedle patch that can be applied to the skin, capture a biomarker and, thanks to its unprecedented sensitivity, allow clinicians to detect the biomarker’s presence.

Researchers at Washington University School of Medicine in St. Louis have found that a protein involved in regulating lipid levels in the liver and blood also promotes development and progression of fatty liver disease and liver cancer in mice.

Researchers at Washington University School of Medicine in St. Louis have found that patients with Barrett’s esophagus may be vulnerable to coronavirus infection from what they swallow.

Faculty experts from across Washington University in St. Louis draw upon their research, their instruction, their experience and their thought leadership to proffer insight and ideas for the new administration, the new beginning.

Dr. Karen Joynt Maddox expects the new Biden/Kamala Harris administration to retool and reinforce Obamacare, rather than the previous administration’s failed attempts to repeal and replace. She offers areas ripe for both quick and gradual change: reinstating health discrimination protection, investing in insurance enrollment, creating the “public option,” and broadening competition in insurance markets.